Prof. Peter
Ka-Fung Chiu is currently an Associate Professor at the Chinese University of
Hong Kong. He is also the principal investigator of the SMART trial, a
multicentre randomized controlled trial comparing MRI prostate pathway and
extended transperineal prostate biopsy pathway in the diagnosis of significant
prostate cancer. He is also leading a study on using biomarkers and MRI for
prostate cancer screening in Hong Kong as part of the CUHK Jockey Club
multi-cancer screening program. He has primary interests in prostate cancer and
benign prostatic hyperplasia. For prostate cancer, he has conducted studies in
novel diagnostic modalities including blood biomarker prostate health index
(phi), urine biomarker spermine, and transperineal MRI-Ultrasound fusion
biopsy.
Prof. Peter
Ka-Fung Chiu is currently an Associate Professor at the Chinese University of
Hong Kong. He is also the principal investigator of the SMART trial, a
multicentre randomized controlled trial comparing MRI prostate pathway and
extended transperineal prostate biopsy pathway in the diagnosis of significant
prostate cancer. He is also leading a study on using biomarkers and MRI for
prostate cancer screening in Hong Kong as part of the CUHK Jockey Club
multi-cancer screening program. He has primary interests in prostate cancer and
benign prostatic hyperplasia. For prostate cancer, he has conducted studies in
novel diagnostic modalities including blood biomarker prostate health index
(phi), urine biomarker spermine, and transperineal MRI-Ultrasound fusion
biopsy.